Combination Products: Jurisdiction and cGMP
A prefilled syringe, a drug-eluting stent and an autoinjector are each a combination product: two or more types of regulated article — drug, device, biological product — brought together. Two questions decide how one is regulated. 21 CFR Part 3 decides which FDA centre leads, by the product’s primary mode of action. 21 CFR Part 4 decides which manufacturing requirements apply, and lets a manufacturer meet all of them through one operating system built on either the drug cGMPs or the device Quality Management System Regulation, plus named provisions from the other.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
What Counts as a Combination Product
Section 3.2(e) of 21 CFR defines four kinds. A single-entity product is two or more regulated components physically, chemically or otherwise combined and produced as one — a drug-coated device, a prefilled syringe. A co-packaged product is separate products packaged together as a unit — a kit with a drug vial and its delivery device. The third and fourth kinds are cross-labelled: a product packaged separately whose labelling says it is for use only with an individually specified approved product, where both are needed for the intended effect and approval would require the other’s labelling to change; and the investigational equivalent.
The constituent parts keep their identities. Part 4 calls each drug, device or biological product within the combination a constituent part, and states that a device constituent part is a finished device for QMSR purposes and a drug constituent part is a drug product for the drug cGMPs.
Which Centre Leads: Primary Mode of Action
FDA assigns a combination product to CDER, CDRH or CBER by its primary mode of action — the single mode of action that provides the most important therapeutic action, meaning the one expected to make the greatest contribution to the overall intended therapeutic effects (21 CFR 3.2(m), 3.4(a)). The regulation defines the three modes: biological product action, device action (meeting the device definition and not achieving its primary intended purposes through chemical action or metabolism), and drug action.
Where FDA cannot determine with reasonable certainty which mode contributes most, it applies an algorithm (3.4(b)): first, the centre that regulates other combination products presenting similar questions of safety and effectiveness; failing that, the centre with the most expertise in the most significant questions the product raises.
The lead centre runs the premarket review and the product’s regulation, with other centres consulting. The application type usually follows: a device-led product is typically cleared or approved through a device submission, a drug-led product through an NDA or ANDA, a biologic-led product through a BLA.
Requesting a Designation
Where assignment is unclear or disputed, the sponsor files a Request for Designation with FDA’s product jurisdiction officer before any premarket application (21 CFR 3.7). It describes the product, its composition and manufacture, every known mode of action, the sponsor’s view of the primary one and the basis for it, and the sponsor’s recommended centre.
FDA checks the request for completeness within 5 working days and issues a letter of designation within 60 days of the filing date. If it does not, the sponsor’s recommended centre becomes the designated centre (3.8(b)). A sponsor may ask for reconsideration within 15 days, in no more than 5 pages and without new information. Once issued, the designation changes only with the sponsor’s consent or, without it, to protect public health or for other compelling reasons (3.9).
Which cGMPs Apply: Part 4 and the Streamlined Approach
Section 4.3 applies each constituent part’s own requirements: 21 CFR 210/211 for a drug, Part 820 for a device, Parts 600–680 for a biological product, Part 1271 for an HCT/P, and Part 213 for a medical gas. For single-entity and co-packaged products, section 4.4 offers two ways to comply: demonstrate compliance with every applicable set in full, or use the streamlined approach.
Under the streamlined approach, a drug-cGMP-based operating system must also satisfy named device provisions. Since the QMSR took effect on 2 February 2026, those are ISO 13485 clauses incorporated through §820.7 together with certain QMSR sections: management responsibility (4.1, 5, 6.1 and §820.10), design and development (7.3) with documented risk management, purchasing (7.4), data analysis, improvement and complaint handling (8.2.2, §820.35(a), 8.4, 8.5), installation (7.5.3) and servicing (7.5.4, §820.35(b)).
A QMSR-based system must instead also satisfy eight drug cGMP sections: component testing (211.84), yield (211.103), tamper-evident packaging for OTC products (211.132), expiration dating (211.137), testing and release (211.165), stability (211.166), special testing (211.167) and reserve samples (211.170). Biological product and HCT/P constituent parts bring all of their own requirements regardless of base.
Separate Sites, and When the Streamlined System Starts
While a constituent part is made at a separate facility from the others, that facility must comply with all the requirements for its own type of constituent part (4.4(c)). The streamlined operating system may begin only once two or more types of constituent part have arrived at, or are being manufactured at, the same facility (4.4(d)).
The sets of rules supplement one another; where they conflict, the provision most specifically applicable to the constituent part prevails (4.4(e)). FDA’s January 2017 guidance explains the 2013 rule in detail. It predates the QMSR, so its device-side discussion refers to the former Quality System regulation; read it alongside the current text of §4.4(b)(1).
Postmarketing Safety Reporting
Part 4 Subpart B applies to marketed combination products. The combination product applicant reports under the rules of its own application type — Parts 803 and 806 for a device application, Part 314 for an NDA or ANDA, Parts 600 and 606 for a BLA — and additionally files the constituent-specific reports the other parts would trigger (4.102).
A product with a device constituent part adds five-day reports, malfunction reports, and correction or removal reports. One with a drug constituent part adds field alert reports and fifteen-day reports; one with a biological constituent part adds biological product deviation reports and fifteen-day reports. Under a device application, the fifteen-day reports are due within 30 calendar days instead of 15. Investigational products are outside Subpart B.
FREQUENTLY ASKED
Is a prefilled syringe regulated as a drug or a device?
As a combination product. Its lead centre depends on its primary mode of action, which for a drug delivered by a syringe is usually the drug; its manufacturing must meet both the drug cGMPs and the device QMSR, which Part 4 lets the manufacturer do through one operating system with the called-out provisions from the other.
What happens if FDA does not answer a Request for Designation?
If the product jurisdiction officer has not issued a letter of designation within 60 days of the filing date, the centre the sponsor recommended in the request becomes the designated centre (21 CFR 3.8(b)).
Did the QMSR change the streamlined approach?
Yes. Since 2 February 2026, a drug-cGMP-based system meets the device side through named ISO 13485 clauses, incorporated by reference through §820.7, and certain QMSR sections, rather than through the former Quality System regulation sections. The structure — a base system plus called-out provisions — is unchanged.
Do both constituent-part manufacturers need the full streamlined system?
No. While a constituent part is made at a separate facility, that facility complies with the requirements for its own type of constituent part. The streamlined system applies where the constituent parts come together at the same facility.
The inspection-readiness playbook for this topic
PUT THIS PLAYBOOK TO WORK
- HOW-TO GUIDEHow to Set Up cGMP for a Combination Product →Choose the operating system for a drug–device or biologic–device product and prove it meets both sets of requirements.
- TEMPLATECombination Product cGMP Compliance Plan →
A free account keeps what you save, remembers where you are across devices, and can send you the weekly regulatory briefing. Create a free account